Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
BMC Cancer|May 22, 2004
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activitiesBarry V Fortner, Kurt Tauer, Ling Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2009
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancerL Johnetta Blakely, Lee Schwartzberg, Mark Keaton, et al.
Current Medical Research and Opinion|February 12, 2011
Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)Lee Schwartzberg, Stephen Szabo, James Gilmore, et al.
Springerplus|September 29, 2015
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studiesJoyce O'Shaughnessy, Kristi McIntyre, Lee Schwartzberg, et al.
Clinical Lung Cancer|May 28, 2019
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum ChemotherapyLee Schwartzberg, Beata Korytowsky, John R Penrod, et al.
BMC Cancer|June 15, 2019
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancerLee Schwartzberg, Kristi McIntyre, Sharon Wilks, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 17, 2024
The impact of cancer-related diarrhea on changes in cancer therapyAbdullah Aleem, Maya Charuni Sarihan, Pablo C Okhuysen, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 16, 2017
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related eventsT Christopher Bond, Erika Szabo, Susan Gabriel, et al.
Springerplus|June 3, 2015
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancerHelen Kent Chew, Lee Schwartzberg, Suprith Badarinath, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2016
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialIan Olver, Christina H Ruhlmann, Franziska Jahn, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
BMC Cancer|May 22, 2004
Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activitiesBarry V Fortner, Kurt Tauer, Ling Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 27, 2009
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancerL Johnetta Blakely, Lee Schwartzberg, Mark Keaton, et al.
Current Medical Research and Opinion|February 12, 2011
Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)Lee Schwartzberg, Stephen Szabo, James Gilmore, et al.
Springerplus|September 29, 2015
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studiesJoyce O'Shaughnessy, Kristi McIntyre, Lee Schwartzberg, et al.
Clinical Lung Cancer|May 28, 2019
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum ChemotherapyLee Schwartzberg, Beata Korytowsky, John R Penrod, et al.
BMC Cancer|June 15, 2019
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancerLee Schwartzberg, Kristi McIntyre, Sharon Wilks, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 17, 2024
The impact of cancer-related diarrhea on changes in cancer therapyAbdullah Aleem, Maya Charuni Sarihan, Pablo C Okhuysen, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 16, 2017
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related eventsT Christopher Bond, Erika Szabo, Susan Gabriel, et al.
Springerplus|June 3, 2015
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancerHelen Kent Chew, Lee Schwartzberg, Suprith Badarinath, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2016
2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialIan Olver, Christina H Ruhlmann, Franziska Jahn, et al.
Pageof 12